Roivant Sciences Ltd. 8-K

What Happened

• Roivant Sciences Ltd. reported on March 3, 2026 (Form 8-K, Item 7.01) that the U.S. Food and Drug Administration has accepted the New Drug Application (NDA) for brepocitinib, submitted by its subsidiary Priovant Therapeutics, and has granted the NDA Priority Review. The company attached a press release as Exhibit 99.1 to the 8-K.

Key Details

• Drug and indication: brepocitinib for the treatment of dermatomyositis.
• Filing party: Priovant Therapeutics, a Roivant subsidiary.
• SEC filing date: March 3, 2026 (Form 8-K, Item 7.01; press release Exhibit 99.1).
• Regulatory status: FDA acceptance of the NDA and designation of Priority Review.

Why It Matters

• FDA acceptance and Priority Review are formal steps that advance brepocitinib through the regulatory process and increase clarity on its potential path to approval.
• For investors, this is a material regulatory update from Roivant/Priovant that could affect development timeline and commercialization prospects for the drug if approval follows.
• The disclosure was made under Regulation FD via an 8-K and accompanied by a press release, signaling the company’s intent to communicate this material development broadly and promptly.